STOCK TITAN
  1. Home
  2. Sec-filings
  3. PCVX
  4. [8-K] Vaxcyte, Inc. Reports Material Event

Vaxcyte (NASDAQ: PCVX) launches $500M common stock sales plan

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Vaxcyte, Inc. entered a new at-the-market stock offering program allowing it to sell up to $500,000,000 of common stock through Leerink Partners as placement agent under an existing shelf registration on Form S-3.

The shares may be sold from time to time on Nasdaq or other permitted markets, with Leerink Partners earning up to 3.00% of gross proceeds. Vaxcyte simultaneously terminated its prior Open Market Sale Agreement with Jefferies, under which it had previously sold approximately $270.3 million of common stock.

Positive

  • None.

Negative

  • None.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Understanding 8-K Material Events →
false 0001649094 0001649094 2026-02-24 2026-02-24
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 24, 2026

 

 

VAXCYTE, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39323   46-4233385

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

825 Industrial Road  
Suite 300  
San Carlos, California   94070
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 837-0111

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   PCVX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 8.01.

Other Events.

Sales Agreement

On February 24, 2026, Vaxcyte, Inc. (“Vaxcyte”) entered into a sales agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Placement Agent ”), pursuant to which the Company may sell shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of up to $500,000,000 (the “Shares”), from time to time through the Placement Agent. The Shares are registered with the Securities and Exchange Commission (the “Commission”) pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333- 279735) (as amended and/or supplemented from time to time, the “Registration Statement”) that automatically became effective under the Securities Act of 1933, as amended (the “Securities Act”) upon filing on May 24, 2024. The Company has filed with the Commission a prospectus supplement, dated February 24, 2026, to the base prospectus included in the Registration Statement, in connection with the offer and sale of the Shares from time to time in the future.

Subject to the terms and conditions of the Sales Agreement, the Placement Agent will use commercially reasonable efforts consistent with its normal sales and trading practices and applicable state and federal laws, rules and regulations and the rules of the Nasdaq Global Select Market to sell such Shares up to the number or amount in accordance with instructions from the Company. Unless otherwise instructed by the Company, sales, if any, of the Shares made through the Placement Agent may be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415 of the Securities Act, including sales made directly on or through Nasdaq Global Select Market, on or through any other existing trading market for the Common Stock or to or through a market maker or, if expressly authorized by the Company by negotiated transactions. The Placement Agent will be entitled to compensation of up to 3.00% of the gross proceeds from the sale of the Shares sold through the Placement Agent from time to time pursuant to the terms of the Sales Agreement.

The Company is not obligated to sell, and the Placement Agent are not obligated to buy or sell, any Shares under the Sales Agreement. No assurance can be given that the Company will sell any Shares under the Sales Agreement, or, if it does, as to the price or number of Shares that it sells, or the dates when such sales will take place.

The Company made certain customary representations, warranties and covenants concerning the Company and the Registration Statement in the Sales Agreement and also agreed to indemnify the Placement Agent against certain liabilities, including liabilities under the Securities Act.

A copy of the Sales Agreement is attached to this Current Report on Form 8-K (this “Report”) as Exhibit 1.1 and is incorporated herein by reference. The summary set forth above is qualified in its entirety by reference to Exhibit 1.1. A copy of the opinion of Skadden, Arps, Slate, Meagher & Flom LLP relating to the legality of the issuance and sale of the Shares is attached as Exhibit 5.1 hereto.

Effective as of February 24, 2026, the Company terminated the Open Market Sale Agreement, dated as of July 1, 2021 and amended on February 27, 2023 (the “Prior Sales Agreement”), that the Company previously entered into with Jefferies LLC. Prior to termination, the Company sold shares of its Common Stock having an aggregate offering price of approximately $270.3 million pursuant to the Prior Sales Agreement.

 

Item 9.01.

Financial Statements and Exhibits.

 

Exhibit

Number

    Description
 1.1    Sales Agreement, dated February 24, 2026, between the Company and the Placement Agent
 5.1    Opinion of Skadden, Arps, Slate, Meagher & Flom LLP
23.1    Consent of Skadden, Arps, Slate, Meagher & Flom LLP (contained in Exhibit 5.1)
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

(d) Exhibits

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    VAXCYTE, INC.
Date: February 24, 2026     By:  

/s/ Andrew Guggenhime

            Andrew Guggenhime
            President and Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What stock offering program did Vaxcyte (PCVX) establish with Leerink Partners?

Vaxcyte established an at-the-market offering program to sell up to $500,000,000 of common stock through Leerink Partners. Sales can occur over time on Nasdaq or other permitted markets under an effective Form S-3 shelf registration.

How is Leerink Partners compensated under Vaxcyte’s new sales agreement?

Leerink Partners will receive up to 3.00% of the gross proceeds from any Vaxcyte common stock sold through the program. This fee is calculated on each sale completed under the at-the-market arrangement described in the sales agreement.

What happened to Vaxcyte’s prior Open Market Sale Agreement with Jefferies?

Effective February 24, 2026, Vaxcyte terminated its prior Open Market Sale Agreement with Jefferies. Before termination, the company had sold common stock with an aggregate offering price of approximately $270.3 million under that earlier agreement.

Under what registration is Vaxcyte’s new $500 million stock program conducted?

The new at-the-market program uses Vaxcyte’s effective Form S-3 shelf registration statement (File No. 333-279735). A related prospectus supplement dated February 24, 2026 covers the offer and sale of the shares from time to time.

Filing Exhibits & Attachments

5 documents

Other Documents